Cargando…

Population pharmacokinetic and exposure–response analysis of apremilast in Japanese subjects with moderate to severe psoriasis

Apremilast is an orally available phosphodiesterase 4 inhibitor used for the treatment of moderate to severe psoriasis. The aims of this analysis were to develop a population pharmacokinetic (PPK) model of apremilast based on observed data from phase 1 studies combined with clinical trial data from...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okubo, Yukari, Ohtsuki, Mamitaro, Komine, Mayumi, Imafuku, Shinichi, Kassir, Nastya, Petric, Rosemary, Nemoto, Osamu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290614/ https://www.ncbi.nlm.nih.gov/pubmed/34396569 http://dx.doi.org/10.1111/1346-8138.16068

Ejemplares similares

Pharmacodynamic analysis of apremilast in Japanese patients with moderate to severe psoriasis: Results from a phase 2b randomized trial
por: Imafuku, Shinichi, et al.
Publicado: (2020)

Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial
por: Ohtsuki, Mamitaro, et al.
Publicado: (2017)

Long‐term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5‐year extension of a phase 3 study (reSURFACE 1)
por: Imafuku, Shinichi, et al.
Publicado: (2021)

Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64‐week phase 3 study (reSURFACE 1)
por: Igarashi, Atsuyuki, et al.
Publicado: (2021)

Biologics for Psoriasis during the COVID-19 Pandemic
por: Kamiya, Koji, et al.
Publicado: (2021)

Apremilast Prolongs the Time to First Biologic Therapy in Japanese Patients with Psoriasis
por: Tanaka, Masayuki, et al.
Publicado: (2021)

Risk Factors for the Development of Psoriasis
por: Kamiya, Koji, et al.
Publicado: (2019)

Long‐term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3‐year results of a double‐blind extension study
por: Okubo, Yukari, et al.
Publicado: (2019)

Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double‐blind, phase 3 study
por: Asahina, Akihiko, et al.
Publicado: (2016)

Epidemiological survey of patients with pustular psoriasis in the Japanese Society for Psoriasis Research from 2017 to 2020
por: Kamiya, Koji, et al.
Publicado: (2022)

Epidemiological survey of the psoriasis patients in the Japanese Society for Psoriasis Research from 2013 to 2018
por: Kamiya, Koji, et al.
Publicado: (2021)

Diagnosis and Intervention in Early Psoriatic Arthritis
por: Hioki, Tomoyuki, et al.
Publicado: (2022)

Epidemiological survey of patients with psoriatic arthritis in the Japanese Society for Psoriasis Research from 2017 to 2020
por: Kamiya, Koji, et al.
Publicado: (2022)

Comparison of Treatment Goals between Users of Biological and Non-Biological Therapies for Treatment of Psoriasis in Japan
por: Okubo, Yukari, et al.
Publicado: (2021)

Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2016)

Drug Survival of Tumor Necrosis Factor-Alpha Inhibitors and Switched Subsequent Biologic Agents in Patients with Psoriasis: A Retrospective Study
por: Kishimoto, Megumi, et al.
Publicado: (2023)

Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis
por: Verbenko, Dmitry A., et al.
Publicado: (2020)

Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study
por: Terui, Tadashi, et al.
Publicado: (2023)

Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study
por: Reich, K., et al.
Publicado: (2018)

Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study
por: Asahina, Akihiko, et al.
Publicado: (2023)

STAT3 Activation in Psoriasis and Cancers
por: Kishimoto, Megumi, et al.
Publicado: (2021)

Pediatric psoriasis treated with apremilast
por: Smith, Rebecca L.
Publicado: (2016)

Erythrodermic Psoriasis Treated with Apremilast
por: Arcilla, John, et al.
Publicado: (2016)

Treatment of erythrodermic psoriasis with apremilast
por: Gioe, Olivia A., et al.
Publicado: (2021)

Role of Matrix Metalloproteinases in Photoaging and Photocarcinogenesis
por: Pittayapruek, Pavida, et al.
Publicado: (2016)

Diversified Stimuli-Induced Inflammatory Pathways Cause Skin Pigmentation
por: Hossain, Md Razib, et al.
Publicado: (2021)

Immunotherapy for the Treatment of Squamous Cell Carcinoma: Potential Benefits and Challenges
por: Ansary, Tuba M., et al.
Publicado: (2022)

Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial
por: Ohtsuki, Mamitaro, et al.
Publicado: (2019)

Real-world Efficacy and Safety of Apremilast Monotherapy in the Management of Moderate-to-severe Psoriasis
por: Shah, Bela J., et al.
Publicado: (2020)

Efficacy and Safety of Apremilast in the Treatment of Patients with Mild-to-Moderate Psoriasis in Japan: Results from PROMINENT, A Phase 3b, Open-Label, Single-Arm Study
por: Okubo, Yukari, et al.
Publicado: (2022)

Apremilast in the Treatment of Plaque Psoriasis: Differential Use in Psoriasis
por: Gao, Jia C, et al.
Publicado: (2022)

Apremilast or Methotrexate: The Arrows in the Quiver for Psoriasis
por: Panda, Gautam, et al.
Publicado: (2023)

Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch
por: Ohtsuki, Mamitaro, et al.
Publicado: (2017)

Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: Effect of Demographics and Baseline Disease Characteristics on Efficacy
por: Imafuku, Shinichi, et al.
Publicado: (2021)

Guselkumab, an anti‐interleukin‐23 monoclonal antibody, for the treatment of moderate to severe plaque‐type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double‐blind, placebo‐controlled study
por: Ohtsuki, Mamitaro, et al.
Publicado: (2018)

Diagnostic Clues for Pagetoid Bowen's Disease
por: Chiang, Binluen, et al.
Publicado: (2020)

Inflammatory Molecules Associated with Ultraviolet Radiation-Mediated Skin Aging
por: Ansary, Tuba M., et al.
Publicado: (2021)

Inflammation Causes Exacerbation of COVID-19: How about Skin Inflammation?
por: Komine, Mayumi, et al.
Publicado: (2022)

Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis Registry
por: Gottlieb, Alice B., et al.
Publicado: (2021)

Safety, efficacy, and drug survival of the infliximab biosimilar CT‐P13 in post‐marketing surveillance of Japanese patients with psoriasis
por: Morita, Akimichi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vuri64rjcf56lphc0pu52n48bm